摘要
目的 使用VOSviewer对地奥心血康的文献进行计量学研究,揭示国内学者对该药的主要研究领域和热点。方法 中文文献通过中国知网、万方数据知识服务平台、维普网,英文文献选择PubMed及Web of Science核心合集数据库进行检索,数据采集时间为建库至2021年12月,并通过VOSviewer、Excel、Pajek对地奥心血康的研究成果进行分析。结果 通过PubMed和Web of Science核心合集数据库检索得到地奥心血康相关的文献共14篇,因文献数量较少及中英文数据导入VOSviewer兼容性问题,未利用VOSviewer工具进行直接分析。共纳入597篇文献。分析显示,研究文献数量呈增长趋势,文献发表时间集中在1993—2012年,近10年有所减少。其中,国家自然科学基金和学者周正质贡献最多。此外,徐持华发表的论文被引用次数最多。地奥心血康治疗冠心病和心绞痛是研究热点,更多集中于基础研究,临床试验较少。结论 地奥心血康相关的文献多数为国内研究,且集中于冠心病和心绞痛相关基础,未来在非冠心病、心绞痛等领域的研究可能成为研究热点及该药的发展方向。随着地奥心血康在国内重视程度提升及有关非冠心病领域的相关研究的完善和延伸,未来该药的临床使用和市场可能会得到进一步的扩展。
Objective To study bibliometrics on the research literature of Di'ao Xinxuekang,and to reveale the main research fields and hot spots of domestic scholars on this drug.Methods The Chinese literature was searched through CNKI,Wanfang Data,and VIP,and the English literature was selected from PubMed and Web of Science core collection databases.The data collection time was from the establishment of the database to December 2021.Through VOSviewer,Excel,and Pajek,the research results of Di'ao Xinxuekang were analyzed.Results A total of 14 literatures related to Di'ao Xinxuekang were retrieved through PubMed and Web of Science Core Collection database.Due to the small number of literatures and the compatibility of Chinese and English data imported into VOSviewer,VOSviewer tool was not used for direct analysis.Finally,597 articles were included.The analysis showed that the number of research literature showed increasing trend,and the publication time of literature was concentrated in 1993—2012,which had decreased in the past 10 years.Among them,the National Natural Science Foundation and scholar Zhou Zhengzhi contributed the most.In addition,Xu Zhihua published the most frequently cited papers.Di'ao Xinxuekang in the treatment of coronary heart disease and angina pectoris was research hotspot,with more focus on basic research and less clinical trials.Conclusion Most of the literatures related to Di'ao Xinxuekang are domestic studies,and they focus on basic study related to coronary heart disease and angina pectoris.Future studies in non-coronary heart disease,angina pectoris and other fields may become the research hotspot and development direction of this drug.With the increase of attention in China and the improvement and extension of related research in non-coronary heart disease fields,the clinical use and market of this drug may be further expanded in the future.
作者
严宇庭
鲍柏屹
徐凯
曹兆流
李歆
YAN Yuting;BAO Baiyi;XU Kai;CAO Zhaoliu;LI Xin(School of Pharmacy,Nanjing Medical University,Jiangsu Province,Nanjing211166,China;Department of Pharmacy,Nanjing Qixia District Hospital,Jiangsu Province,Nanjing210046,China)
出处
《中国医药导报》
CAS
2024年第13期42-46,共5页
China Medical Herald
基金
国家自然科学基金资助项目(72074123、71673147)
江苏省政策引导类计划(软科学研究)专项资金项目(BR2020043)。
关键词
地奥心血康
中成药
VOSviewer
文献计量学
冠心病
心绞痛
Di'ao Xinxuekang
Chinese patent medicine
VOSviewer
Bibliometrics
Coronary Heart Disease
Angina pectoris
